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ABSTRACT 
Introduction: Clostridium difficile (C. difficile) is a major 
nosocomial infectious agent in hospitals. Previous studies 
have addressed the high proportion of infection episodes 
that are overlooked in health care facilities.
Objective: the main aim of this study was to characterize 
C. difficile clinical cases that occurred in a secondary care 
hospital during a five-month period.
Material and methods: for this purpose, a total of 137 stool 
samples from the same number of patients with diarrhea 
were analyzed for the presence of C. difficile by culture tech-
niques. An enzyme immunoassay (EIA) test for the detec-
tion of C. difficile and its toxins was also used in 50 cases 
(36.5%) for diagnostic purposes.
Results: a total of 14 (10.2%) C. difficile isolates were 
obtained, of which nine (64.3%) were toxigenic. A mean inci-
dence of 3.2 episodes of C. difficile infections (CDI) per 10,000 
patients-days was estimated for the study period. Around 
56% of the CDI cases were determined as hospital-acquired, 
whereas 44% originated in the community. Among these, 
only two episodes (22.2%) were detected in the hospital by 
the EIA test, which indicated that the hospital CDI detection 
protocol needed to be revised. One unusual C. difficile iso-
late was negative for all toxin genes examined and also for 
the non-toxigenic strain assay, which highlights the need to 
perform genome sequencing to study its pathogenicity locus 
insertion site organization. A stable metronidazole-resistant 
C. difficile strain and three strains showing multidrug resis-
tance were detected in this study, suggesting that C. difficile 
antimicrobial susceptibility surveillance programs should be 
established in this health-care facility.
Key words: Clostridium difficile. Humans. Metronidazole. 
PCR-ribotyping. Immunoassay.
INTRODUCTION
Clostridium difficile (C. difficile) is an anaerobic gram-pos-
itive bacillus and the principal causative agent of nosoco-
mial diarrhea in developed countries. This organism also 
causes 10-25% of antibiotic associated diarrhea (1). The 
main predisposing factors for C. difficile infections (CDI) 
include advanced age, a stay at a health care facility and 
the use of broad-spectrum antibiotics (2). Although met-
ronidazole and vancomycin are the first choice antibiotics 
for CDI treatment, C. difficile strains increasingly show a 
low susceptibility or resistance to these antibiotics, espe-
cially metronidazole (3). The epidemiology of C. difficile 
has changed and now is considered as one of the main 
nosocomial infectious agents. Clostridium difficile is also 
increasingly reported as a cause of community-acquired 
infections (CA-CDI) and some common ribotypes (RT) (e.g., 
RT078) have been isolated from animals and the environ-
ment, suggesting an inter-species transmission (4).
The Center for Disease Control and Prevention (CDC) 
included C. difficile within the immediate urgent threat 
to public health category due to its unique relationship 
with antibiotic use and resistance (5). In Europe, C. diffi-
cile accounts for 172,000 cases/year with an attributable 
mortality of 9% (6). Besides, Spain seems to be one of the 
many European countries that have experienced a signif-
icant growth of CDI (7). In 2014, the first autochthonous 
non-severe CDI produced by ribotype 027 was reported in 
this country (8). Since then, the incidence of this type has 
increased in Spain and has produced several outbreaks in 
different hospitals (9).
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Previous studies have addressed the high proportion of 
CDI episodes that are undiagnosed or misdiagnosed in 
health care facilities (2). This common situation occurs as 
a consequence of non-optimal laboratory procedures for 
the diagnosis of C. difficile clinical cases or the lack of clin-
ical suspicion, mainly in young people or non-hospitalized 
patients (10). Therefore, the implementation of surveillance 
programs that are able to detect and control endemic and 
epidemic C. difficile strains and to assess their antimicrobial 
susceptibilities is of utmost importance. 
The main aim of this study was to detect and characterize 
the CDI clinical episodes occurring in a secondary hospi-
tal during a five-month period. Thus, CDI incidence was 
estimated and antibiotic susceptibility, toxin genotype and 
molecular characterization (PCR-ribotyping, toxinotyping 
and multi-locus sequence typing or MLST) of C. difficile 
isolates were studied. In addition, the number of CDI cases 
overlooked was estimated via an analysis of all unformed 
stools, regardless of the request of the charge practitioner 
and the origin of the samples.
PATIENTS AND METHODS
Study design
A five-month prospective study of C. difficile infection was 
performed between August and December 2013 at the Hos-
pital Royo Villanova (HRV, secondary care hospital, Zarago-
za, Spain). The study was performed with the permission 
and also under the supervision of the Ethics Committee of 
Clinical Research of Aragón (CEICA, CP05/2014). The HRV 
has 266 beds (ten in the Intensive Care Unit [ICU]) and 
serves an area of approximately 200,000 inhabitants. The 
presence of C. difficile was assessed in all diarrheic samples 
(inpatients and outpatients) submitted to the Microbiology 
Service for toxigenic culture, regardless of the request of 
the charge physician. Samples from children younger than 
two years were excluded from the study due to the uncer-
tain role of C. difficile toxins in this age group (10). The CDI 
diagnostic protocol established in the hospital was followed 
at the time of the sampling. Furthermore, diarrheic feces 
studied by microbiological culture from patients under 
antibiotic treatment and/or hospitalized were also tested 
using a membrane enzyme immunoassay (EIA), following 
the manufacturer’s instructions. This test is designed for the 
simultaneous detection of C. difficile glutamate dehydroge-
nase antigen (GDH) and toxins A and B (C. DIFF QUIK CHEK 
COMPLETE®, Techlab, Orlando, FL, USA) (2).
A CDI case was defined as a case of diarrhea or toxic mega-
colon and a positive laboratory assay for C. difficile toxins 
in stools or a toxin-producing C. difficile isolate (detected 
by culture or other means) (11). In addition, information 
about the origin of the case (HC-CDI: healthcare-associat-
ed; CA-CDI: community-associated; and UA-CDI: unknown 
association) (11), gender, age, antibiotic treatment, prior 
diseases within three months before the start of diarrhea 
(12) and previous CDI episodes were collected from each 
patient from medical records.
The presence/absence of disbiosis was also recorded for 
each patient when available. In this study, the presence 
of disbiosis was defined as the absence of the growth of 
enterobacteria on routine microbiological media used for 
feces culture, overgrowth of Gram-positive microorganisms 
and/or yeast and the absence of lactose positive bacteria. 
The media used for this purpose were blood agar, Salmo-
nella Shigella agar, Hektoen agar and Selenite broth (data 
not shown).
Bacterial isolation and molecular characterization
Isolation of C. difficile from stool samples, molecular char-
acterization of the strains obtained (i.e., tpi housekeeping 
and toxin genes detection by PCR), the identification of 
non-toxigenic strains and PCR-ribotyping were performed. 
In addition, the minimum inhibitory concentration (MIC) 
to vancomycin (VA; range: 0.016-256 µg/ml), metronidazole 
(MZ; range: 0.016-256 µg/ml), moxifloxacin (MX; range: 
0.02-32 µg/ml), erythromycin (ER; range: 0.016-256 µg/ml), 
clindamycin (CM; range: 0.016-256 µg/ml) and tetracycline 
(TC; range: 0.016-256 µg/ml) was also performed, as pre-
viously described (13). The breakpoints for clindamycin, 
moxifloxacin and metronidazole resistance were those 
established by the Clinical and Laboratory Standards Insti-
tute (CLSI) (14) for anaerobic bacteria. The breakpoint for 
tetracycline was ≥ 8 µg/ml (15). The remaining breakpoints 
were based on the literature (16). A PCR-RFLP (restriction 
fragment length polymorphism) based toxinotyping pro-
tocol was performed for all the toxigenic strains with the 
purpose of analyzing the variability of A and B toxin genes 
(A3 and B1 fragments, respectively) (17). Furthermore, 
strains with unexpected results, i.e. negative PCR results 
for tcdA and tcdB genes and also non-toxigenic assay, were 
further studied by toxinotyping (A1, A2, A3, B1, B2 and B3 
fragments) in order to detect the possible presence of toxin 
gene fragments.
The population structure (phylogeny) of the C. difficile 
strains obtained in this study was studied by multi-locus 
sequence typing (MLST) (18). The allele and sequence 
type (ST) designation was determined from the C. difficile 
PubMLST website (http://pubmlst.org/cdifficile/). A maxi-
mum likelihood tree with 1,000 bootstrap replicates was 
constructed based on the Kimura 2-parameter model (19). 
A total of 37 strains were used for this purpose: 14 from 
this study (Hu isolates) (Table 1), four isolates from other 
studies from our research group (RC10, 5754, RF17 and 
E6) (20,21) and 19 from the PubMLST database, in order 
to provide a context for the C. difficile population (ST1, 
ST3, ST5, ST11, ST32, ST37-39, ST41, ST67, ST96, ST122, 
ST177-181, ST200 and ST206). The percentage of trees in 
which the associated taxa clustered together is shown next 
to the branches. Initial tree(s) for the heuristic search were 
obtained by applying the neighbor-joining method to a 
matrix of pair-wise distances estimated using the maxi-
mum composite likelihood approach. Evolutionary analy-
ses were conducted in MEGA7 (22).
The stability of metronidazole-resistant strains for those 
isolates that showed a breakpoint ≥ 32 µg/ml was assessed 
by seven serial passages over 14 days on Brucella blood 
agar plates, without antibiotics (23). Subsequently, the MIC 
to metronidazole was tested again via an Etest as described 
above. Resistance was considered as stable when the MIC 
of metronidazole against C. difficile remained (within ± 
1 dilution) after the passages. Resistance was considered 
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five-month period. An EIA test was also performed in 50 
cases (36.5%) in the hospital for diagnostic purposes. A 
total of 14 (10.2%) C. difficile isolates were obtained; nine 
(64.3%) were toxigenic (Table 1). A mean incidence of 3.2 
cases/10,000 patient-days was determined in the hospital 
during the study period; 55.6% (5/9) of cases were HA-CDI 
and 44.4% (4/9) were CA-CDI.
All toxigenic strains (n = 9) harbored the tcdA and tcdB 
genes. However, one of them had a partial deletion in the 
tcdA gene (amplicon size 700 bp; Hu70 strain). Only one 
(11.1%) isolate yielded a positive result for the CDT genes 
cdtA/cdtB. Non-toxigenic strains (35.7%) yielded a positive 
result for the cdu1/cdd1 PCR, except for one case which 
was negative for this test (Hu25 strain). This isolate was also 
negative to the toxinotyping scheme (A1, A2, A3, B1, B2 and 
B3 fragments) and was classified into ST311 (MLST), which 
has not been assigned to a clade yet (http://pubmlst.org/
cdifficile/) (Fig. 1). A total of 13 and three different PCR-ribo-
types and toxinotypes were identified, respectively. Results 
are summarized in table 1. Twelve different sequence types 
belonging to at least three distinct clades were detected. 
The phylogenetic tree using MEGA7 was drawn to scale, 
with branch lengths measured as the number of substitu-
tions per site. The phylogenetic analysis involved 37 nucle-
otide sequences: 14 belonging to this study, four from 
previous studies of our research group and 19 from the 
database (Fig. 1).
Description of patients
The population studied was mainly formed by female 
patients (61.3%) and most were older than 16 years of age 
(97.8%) (median age: 64 years old; range: 5-101) and orig-
inated from the Emergency Service (51.8%). In addition to 
as unstable when resistant strains became susceptible (˂ 
32 µg/ml) after the passages.
Data analysis
Incidence was calculated as the number of CDI episodes 
diagnosed at the hospital per 10,000 patients-days (includ-
ing in- and outpatients) during the study period (24). Major 
patient characteristics including age, gender, the origin of 
patients (ward facility), the use of any antibiotic or comor-
bidity (previous three months), and suspicion of CDI and 
disease characteristics were determined. As the age vari-
able (continuous variable) did not follow a normal distri-
bution, it was categorized rather than performing a math-
ematical transformation. This aided in the interpretation 
of the results obtained and the categories were based on 
biological criteria as follows: 15 years old was the limit of 
childhood, 16 to 64 years was defined as adulthood and the 
third category was defined as 65 years and over as this is 
the age limit set for the CDI risk population. The association 
between patient characteristics (Table 2) and infection was 
assessed using the Pearson’s Chi-square test or Fisher’s 
exact test for categorical variables. The MedCalc Statistical 
Software version 18.2.1 (MedCalc Software bvba, Ostend, 
Belgium) was used to perform the statistical analysis. A 
2-sided p-value of < 0.05 was set as statistically significant.
RESULTS
Bacterial isolation and molecular characterization
A total of 137 samples from the same number of patients 
with diarrhea were included and analyzed for the presence 
of C. difficile by toxigenic microbiological culture over a 
Table 1. Molecular characterization of Clostridium difficile isolates
ID Toxin genes NTS Toxinotype Ribotype MLST
ST Clade
Hu25 - - - 029 311 Unknown
Hu36 tcdA, tcdB, cdtA, cdtB V 078 11 5
Hu70‡ tcdA*, tcdB VIII 017 37 4
Hu72‡ tcdA, tcdB 0 106 42 1
Hu77 - + - 035 107 1
Hu88 - + - 073 109 4
Hu109 tcdA, tcdB 0 154 110 1
Hu112 tcdA, tcdB 0 020 2 1
Hu129 tcdA, tcdB 0 020 2 1
Hu133†,‡ - + - 010 15 1
Hu138 tcdA, tcdB 0 110 19 1
Hu139 - + - 039 26 1
Hu162 tcdA, tcdB 0 014 26 1
Hu181 tcdA, tcdB 0 New 6 1
ID: sample identification; NTS: non-toxigenic strains PCR; MLST: multilocus sequence typing; ST: sequence type. *Deleted tcdA gene, 700bp. †Metronidazole resistant strain. ‡Multidrug resistant 
isolates.
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C. diffi cile, other enteric pathogens were detected (HRV, 
Clinical Microbiology Service) as follows: Salmonella enter-
ica (8.8%), Aeromonas spp. (5.1%), rotavirus (1.5%) and oth-
ers (2.2%; Hafnia alvei, Giardia lamblia and Cryptosporidi-
um spp.). C. diffi cile was detected in two patients who also 
presented other enteric microorganisms (Salmonella enter-
ica and rotavirus). Considering the nine toxigenic isolates 
detected, fi ve strains (55.6%) were obtained from patients 
located in the Emergency Department, three (33.3%) in 
Internal Medicine and one (11.1%) in Gastroenterology. No 
relationship was observed between the presence of C. diffi -
cile and the factors considered. All results are summarized 
in table 2. 
None of the toxigenic C. diffi cile positive patients suffered 
a CDI episode during the previous eight weeks. Five of nine 
(55.6%) patients suffering from CDI were under antibiotic 
treatment at the time of sampling or during the previous 
three months; the penicillin-β-lactamase inhibitor combina-
tion was the most frequently used class (Table 3). Only two 
(22.2%) patients did not suffer from any other underlying 
disease within the three months before the onset of diar-
rhea. The remaining patients (n = 7) suffered cardiovascular 
comorbidities (57.1%), gastrointestinal disease (i.e., ulcer-
ative colitis) (42.8%), nephro-urologic pathologies (28.6%), 
obesity (14.3%) and/or respiratory disorders (14.3%). None 
of the patients had diarrhea for more than three weeks 
and feces were not mixed with blood or other pathologi-
cal products. Four of nine patients had fever (> 38 °C) and 
abdominal pain. Two patients presented with vomiting and 
Table 2. Characteristics of patients included in the study
n = 137 n (%) Non toxigenic strains (%)* p-value
Age groups of patients 0.51
 2-15 years 3 (2.2) -
 16-64 years 67 (48.9) 3 (4.5)
 ≥ 65 years 67 (48.9) 6 (9)
Sex 0.48
 Females 84 (61.3) 7 (8.3)
 Males 53 (38.7) 2 (3.8)
Origin of patients (ward location) 0.87
 Emergency Service 71 (51.8) 5 (7)
 Internal Medicine 40 (29.2) 3 (7.5)
 Gastroenterology 11 (8) 1 (9.1)
 Intensive Care Unit (ICU) 5 (3.7) -
 Other† 10 (7.3) -
Disbiosis‡ 0.38
 Yes 7 (5.1) 1 (14.3)
 No 130 (94.9) 8 (6.1)
Presence of other enteric pathogens 0.09
 Yes 29 (21.8) 4 (13.7)
 No 108 (78.9) 5 (4.8)
*Percentage of toxigenic strains in relation to the number of samples analysed in each group. †Hematology, Endocrinology, Cardiology, Preventive Medicine, Pneumology, Neurology and General 
Surgery. ‡Absence of regular enteric microbiota (absence of lactose-positive enterobacteria in routine microbiological media (blood agar, Salmonella Shigella (SS) agar, Hektoen agar, and Selenite 
broth) and overgrowth of gram positive bacteria and/or yeasts).
Fig. 1. Molecular phylogenetic analysis (maximum likelihood 
method) from concatenated MLST alleles. Clostridium 
diffi cile isolates corresponding to our collection are shown 
with a circle (ST: sequence type; Hu: human isolate; RC: 
rat intestinal content isolate; 5754: sow vagina isolate; RF: 
environmental rat feces isolate; E: exotic animal isolate).
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leucocytosis (≥ 15,000/µl) was detected in only one patient. 
Serum creatinine was elevated > 50% from the baseline 
before the onset of symptoms in one episode and two CDI 
cases were also associated with colitis (a clinically diag-
nosed based on the presence of diarrhea).
Nine CDI episodes were detected by toxigenic culture in 
this study and only four (44.4%) were diagnosed by the EIA 
test in the hospital via a request from the charge physician. 
Only one (25%) of these cases was positive for the GDH 
antigen and C. difficile toxins (A and B). Of the remaining 
episodes (5/9) detected by toxigenic culture, only one (20%) 
was diagnosed by EIA under the initiative of the Microbi-
ology Service of the hospital, which also yielded a posi-
tive result for antigen and toxins. With regard to the cases 
in which the EIA test was not performed at the hospital, 
patients were ˂ 65 years old, outpatients and/or were not 
treated with antimicrobials at the time they attended the 
hospital. Four of nine patients infected with toxigenic C. 
difficile detected in this study were hospitalized in the same 
room but none of the strains isolated belonged to the same 
ribotype or ST.
Antimicrobial susceptibility testing
Clostridium difficile resistance to CM, ER, MX and TC was 
variable, 35.7% (5/14), 28.6% (4/14), 21.4% (3/14), and 21.4% 
(3/14), respectively. All isolates were fully susceptible to VA 
(≤ 1.5 µg/ml) and MZ (≤ 0.75 µg/ml), except for one strain 
which was resistant to MZ (MIC 32 µg/ml after 24 hours). 
Slow growing MZ-hetero-resistant subpopulations were 
not detected. After performing seven serial passages to the 
MZ-resistant strain, the MIC remained at 32 µg/ml after 48 
hours and 14 days, showing a stable phenotype. Further-
more, three (21.4%) isolates showed multidrug resistance 
(MDR) (Table 1), including the MZ-resistant strain.
DISCUSSION
A mean CDI incidence of 3.2 cases/10,000 patient-days was 
found in this study, which is in close agreement with the 
previously published data in Europe (2.45 [1], 4.1 [25] and 
3.2 [26]). Among the CDI episodes detected by toxigenic 
culture (n = 9), only five (55.5%) were considered for study 
by EIA at the hospital. From these, only two (40%) yielded a 
positive result for the GDH antigen and toxins (2/9 in total, 
22.2%). These results are in agreement with previous stud-
ies that observed a high proportion of undiagnosed or mis-
diagnosed CDI episodes in health care facilities. Diagnostic 
failures may originate due to the implementation of non-op-
timal laboratory procedures for CDI diagnostic (three out of 
five in this study) and/or the lack of clinical suspicion due 
to factors such as a younger age than 65 years (3/9 patients 
in this study), no previous/current antibiotic treatment (3/9 
patients) and/or non-hospitalized patients (4/9 patients) 
(2,10). Thus, as previously proposed, all unformed feces 
should be tested for C. difficile, regardless of their origin 
(10), and CDI diagnostics should not be based exclusively 
on antigen detection methods (27). Other diagnostic tools 
that are more sensitive than EIAs (e.g., qPCR) could be used 
for diagnostic purposes (28).
Multilocus sequence typing is considered to be an appro-
priate method to study C. difficile phylogeny and PCR-ri-
botyping is useful for emergent and epidemic genotypes 
surveillance (29,30). In this study, PCR-ribotyping and 
MLST results showed a high molecular diversity among 
the strains obtained and only RT020 was found in more 
than one patient (Table 1). Both RT020 strains showed the 
same ST by MLST but they were not closely related in time 
(nine days) or space (different rooms and medical services). 
These results indicated that there was no clonal population 
established among diarrheic patients during the study peri-
od. Moreover, it could reflect the different C. difficile types 
that were in the study area during the sampling period. 
The isolation of four genetically different C. difficile strains 
Table 3. Characteristics of patients with Clostridium difficile infection (n = 9 toxigenic isolates)
Epidemiological characteristics n/n (%)
Outpatients (Emergency Service) 5/9 (55.6)
Epidemiological association
 HA-CDI 5/9 (55.6)
 CA-CDI 4/9 (44.4)
Use of any antibiotic during previous 3 months 5/9 (55.6)
 Penicillin-β-lactamase inhibitor combination (amoxicillin clavulanic acid, piperacillin/tazobactam) 5/9 (55.6)
 Fluoroquinolone (levofloxacin) 1/9 (11.1)
 Lincosamide (clindamycin) 1/9 (11.1)
 Nitroimidazole (metronidazole) 1/9 (11.1)
 Aminoglycoside (gentamycin) 1/9 (11.1)
CDI test request by practitioner (EIA) 4/9 (44.4)
Underlying diseases (previous 3 months)
 Yes 7/9 (77.8)
 No 2/9 (22.2)
HA-CDI: hospital acquired Clostridium difficile infection; CA-CDI: community acquired Clostridium difficile infection; CDI: Clostridium difficile infection; EIA: enzyme immunoassay.
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(from the same number of patients) in the same hospital 
room at different times, might reflect previous observations 
that the source of the infection is diverse and does not nec-
essarily originate from another symptomatic patient (31). 
These findings suggest the existence of other contamina-
tion sources such as asymptomatic people in the hospital 
or other environmental reservoirs (31).
The phylogenetic study by MLST revealed that most of the 
C. difficile isolates obtained in this study belonged to clade 
1 (Table 1 and Fig. 1). However, there was one isolate whose 
clade is still unclear; Hu25 (RT029, ST311) (Table 1 and Fig. 
1). We included previously published STs in order to pro-
vide a context for the C. difficile population obtained and 
the Hu25 isolate was shown to have a possible common 
ancestor with ST200. This strain represents a new toxino-
type (XXXII) and produces only toxin B (32) (http://pubmlst.
org/cdifficile/). However, Hu25 was negative for all the toxin 
genes tested (tcdA, tcdB, cdtA and cdtB). The clade in which 
ST200 is located is still unclear but it has been proposed 
as a member of clade 6, based on the comparison of its 
core genome by whole genome sequencing (WGS) (33). 
On the other hand, ST122 has been proposed to belong to 
clades 6 and 1 based on MLST and WGS studies, respec-
tively (34,35). The phylogenetic analysis based on the MLST 
scheme described by Griffiths et al. (2010) revealed that 
ST122 was closely related to clades 1 and 2 and distant from 
ST200 and ST311 (Fig. 1). C. difficile Hu25 was also negative 
for non-toxigenic strains by PCR. The existence of strains 
which harbor an atypical pathogenicity locus (PaLoc) genet-
ic organization has been previously reported and does not 
present the traditional non-coding region which replaces it 
when it is absent (36). Thus, it seems necessary to perform 
further WGS analysis in order to elucidate all these aspects 
for the Hu25 strain.
Common ribotypes have been isolated from humans and 
other animal species in previous studies (4) such as those 
found in this study (Table 1). An example is RT078, which 
has been widely associated with non-human animal species 
(37), supporting the hypothesis of an interspecies transmis-
sion of C. difficile. Non-toxigenic RT010 has been frequently 
associated with dogs and metronidazole resistance (38-42). 
A non-toxigenic RT010 strain was detected in this study, 
which showed stable metronidazole resistance and MDR 
(MIC 32 µg/ml) (Table 1), thus highlighting the importance 
of non-toxigenic strains as antimicrobial resistance deter-
minant reservoirs. C. difficile strains are increasingly report-
ed to be resistant to metronidazole (3) and thus a wise use 
of this drug is of the utmost importance.
The ermB genes are frequently associated with clindamycin 
and erythromycin resistance and mobile genetic elements 
(43). Besides, the wide use of fluoroquinolones in human 
medicine is likely implicated in the widespread emergence 
of drug resistance to this class of antimicrobials (44). In this 
study, three isolates were MDR, including CM and ER resis-
tance, and two were also resistant to MX. All these results 
emphasizes the importance of the implementation of C. dif-
ficile antimicrobial susceptibility surveillance programs in 
health-care facilities. However, these results and those pre-
viously discussed should be interpreted cautiously, as this 
study has some limitations, such as the restricted geograph-
ical distribution of the patients included and the relatively 
low number of samples and C. difficile isolates considered.
In conclusion, the CDI incidence found in this study showed 
that there was no ongoing C. difficile outbreak in the HRV 
nor a clonal population established among diarrheic 
patients during the study period. There was a high propor-
tion of CDI episodes that were undiagnosed or misdiag-
nosed due to non-optimal laboratory procedures for the 
CDI diagnosis and/or a lack of clinical suspicion by prac-
titioners. Thus, all unformed feces should be tested for C. 
difficile, regardless of their origin. Furthermore, CDI diag-
noses should not be based exclusively on antigen detec-
tion methods. The sources of C. difficile infections remain 
elusive in many cases and further epidemiological studies 
are warranted to obtain more information about this aspect 
and to implement more efficacious preventive measures. 
Several ribotypes detected in this study have been previ-
ously isolated from humans and other animal species, sup-
porting the hypothesis of an interspecies transmission of C. 
difficile. The antimicrobial susceptibility results obtained in 
this study emphasized the need to perform routine antimi-
crobial susceptibility testing for all strains of C. difficile in 
health-care facilities. Besides, genome sequencing analyses 
are needed to study the PaLoc genetic organization of the 
unusual C. difficile isolate obtained.
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